CaliPharms, Inc. (KGET) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
KGET, $ (piyasa değeri 0) fiyatla Basic Materials işi olan CaliPharms, Inc.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 57/100 puan alıyor.
Son analiz: 18 Mar 2026CaliPharms, Inc. (KGET) Malzemeler ve Emtia Maruziyeti
CaliPharms, Inc. operates within the evolving medicinal cannabis sector, concentrating on THC and CBD-infused beverages. The company, formerly Kleangas Energy Technologies, shifted its focus in 2017. It faces competition in a dynamic market while striving to establish its brand in the cannabis beverage segment.
Yatırım Tezi
CaliPharms, Inc. presents a high-risk, high-reward investment profile due to its early-stage involvement in the cannabis-infused beverage market. The company's success hinges on its ability to navigate complex regulatory hurdles and establish a strong brand presence. Key value drivers include successful product development, effective marketing, and strategic partnerships. The company's negative P/E ratio of -0.01 and a profit margin of -11861.4% indicate significant financial challenges. Investors should closely monitor the company's cash flow, debt levels, and ability to secure funding for future growth. The high beta of -58.74 suggests extreme volatility relative to the market.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- Negative P/E ratio of -0.01 reflects the company's current lack of profitability.
- Profit Margin of -11861.4% highlights significant operational inefficiencies and challenges in achieving profitability.
- Gross Margin of 100.0% suggests high potential profitability if operational costs are managed effectively.
- Beta of -58.74 indicates an extremely volatile stock, moving inversely to the market.
Rakipler & Benzerleri
Güçlü Yönler
- Focus on the growing cannabis beverage market.
- Potential for first-mover advantage in specific regions.
- Experienced management team with knowledge of the cannabis industry.
Zayıflıklar
- Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals for growth.
- Lack of established brand recognition.
Katalizörler
- Upcoming: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
- Ongoing: Increasing consumer acceptance of cannabis-infused beverages could drive demand and revenue growth.
- Ongoing: Development and launch of new cannabis-infused beverage products could attract new customers.
- Upcoming: Securing partnerships with established beverage distributors could expand market reach.
- Ongoing: Positive clinical trial results for cannabis-based therapies could increase investor confidence.
Riskler
- Potential: Stringent regulations and licensing requirements could limit market access.
- Ongoing: Intense competition from larger cannabis companies could erode market share.
- Potential: Negative public perception of cannabis could hinder demand growth.
- Ongoing: Limited access to capital and funding could constrain growth plans.
- Potential: Product recalls or safety concerns could damage brand reputation.
Büyüme Fırsatları
- Expansion into New Markets: As cannabis legalization expands across the United States, CaliPharms, Inc. has the opportunity to enter new markets. Each new state represents a potential revenue stream, provided the company can navigate the local regulatory environment. The timeline for this growth is dependent on the pace of legalization efforts and the company's ability to secure licenses and distribution agreements. The market size for cannabis beverages is projected to reach billions of dollars in the coming years.
- Product Diversification: CaliPharms, Inc. can expand its product line beyond THC and CBD beverages to include other cannabis-infused products, such as edibles, topicals, and concentrates. This diversification would allow the company to cater to a wider range of consumer preferences and increase its market share. The timeline for product diversification depends on the company's R&D capabilities and its ability to obtain regulatory approval for new products. The market for cannabis-infused products is diverse and growing rapidly.
- Strategic Partnerships: Forming strategic partnerships with established beverage distributors or cannabis retailers can provide CaliPharms, Inc. with access to wider distribution networks and increased brand visibility. These partnerships can accelerate the company's growth and reduce its reliance on direct sales. The timeline for establishing strategic partnerships depends on the company's networking efforts and its ability to negotiate favorable terms. The benefits of strategic partnerships can be significant, including increased revenue and market share.
- Branding and Marketing: Investing in branding and marketing efforts can help CaliPharms, Inc. establish a strong brand identity and differentiate itself from competitors. Effective marketing campaigns can increase consumer awareness and drive sales. The timeline for building a strong brand depends on the company's marketing budget and its ability to create compelling messaging. A strong brand can command premium pricing and increase customer loyalty.
- Research and Development: Investing in research and development can enable CaliPharms, Inc. to develop innovative new products and improve the quality and efficacy of its existing products. This can give the company a competitive advantage and attract new customers. The timeline for R&D depends on the company's resources and its ability to conduct successful clinical trials. Successful R&D can lead to patentable products and increased market share.
Fırsatlar
- Expansion into new markets as cannabis legalization progresses.
- Development of innovative cannabis-infused products.
- Strategic partnerships with established beverage distributors.
Tehditler
- Increasing competition from larger cannabis companies.
- Changing regulations and potential for stricter enforcement.
- Negative public perception of cannabis.
Rekabet Avantajları
- First-mover advantage in specific regional markets.
- Proprietary formulations for THC and CBD beverages.
- Established relationships with cannabis cultivators and distributors.
KGET Hakkında
CaliPharms, Inc., headquartered in Temecula, California, is a participant in the United States' medicinal cannabis industry. The company's primary focus is the development and potential distribution of beverages infused with THC and CBD. CaliPharms, Inc. was originally established under the name Kleangas Energy Technologies, Inc., reflecting an earlier business direction. In January 2017, the company underwent a strategic shift, rebranding itself as CaliPharms, Inc. to align with its new focus on the cannabis market. This transition marked a significant change in business strategy, moving away from energy technologies to capitalize on the emerging opportunities within the medicinal cannabis sector. The company is positioning itself to cater to the growing demand for cannabis-infused products, particularly in the beverage segment. CaliPharms, Inc. is working to establish its presence in a competitive market, navigating the regulatory landscape and consumer preferences within the cannabis industry.
Ne Yaparlar
- Engages in the medicinal cannabis industry in the United States.
- Focuses on the development of THC and CBD beverages.
- Aims to capitalize on the growing market for cannabis-infused products.
- Navigates the regulatory landscape of the cannabis industry.
- Seeks to establish a brand presence in the cannabis beverage segment.
- Works to develop and distribute cannabis-infused beverages.
İş Modeli
- Develops and potentially distributes THC and CBD-infused beverages.
- Aims to generate revenue through the sale of these beverages.
- Focuses on the medicinal cannabis market in the United States.
Sektör Bağlamı
CaliPharms, Inc. operates in the rapidly evolving cannabis industry, specifically targeting the infused beverage market. This sector is characterized by changing regulations, increasing competition, and growing consumer acceptance. The market is driven by the increasing legalization of cannabis for medicinal and recreational purposes in various states. CaliPharms faces competition from established players in the beverage industry and emerging cannabis companies. The company's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.
Kilit Müşteriler
- Consumers seeking medicinal cannabis products.
- Individuals interested in THC and CBD-infused beverages.
- Patients with medical conditions that may benefit from cannabis use.
Finansallar
Grafik & Bilgi
CaliPharms, Inc. (KGET) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Stocks That Hit 52-Week Lows On Tuesday
· 21 Oca 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· 3 Ara 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· 9 Eki 2019
-
Stocks That Hit 52-Week Lows On Tuesday
· 8 Eki 2019
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
KGET için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
KGET için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, KGET'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Sınıflandırma
Sektör Agricultural InputsYönetim: Eric Watson
CEO
Eric Watson serves as the Chief Executive Officer of CaliPharms, Inc. Information regarding Mr. Watson's detailed career history, educational background, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive overview of his professional background and qualifications.
Sicil: Due to limited information, it is not possible to assess Eric Watson's track record at CaliPharms, Inc. or his previous accomplishments in other roles. An evaluation of his strategic decisions, company milestones achieved under his leadership, and overall performance requires additional data.
KGET OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that CaliPharms, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to less stringent regulations and oversight compared to those listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history, distressed financials, or those that choose not to comply with higher reporting standards. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited liquidity and potential for price volatility.
- Lack of regulatory oversight and potential for fraud.
- Uncertainty regarding financial reporting and disclosure.
- Higher risk of delisting or trading suspension.
- Potential for limited access to capital and funding.
- Verify the company's legal status and registration.
- Obtain and review the company's financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk factors.
- Determine the availability of reliable information and disclosures.
- Understand the liquidity and trading characteristics of the stock.
- Company's registration and good standing with regulatory authorities.
- Availability of some financial information, even if limited.
- Active communication with investors and the public.
- Positive media coverage or industry recognition.
- Existence of a functional website and contact information.
Yatırımcılar CaliPharms, Inc. (KGET) Hakkında Ne Soruyor
KGET için değerlendirilmesi gereken temel faktörler nelerdir?
CaliPharms, Inc. (KGET) şu anda yapay zeka skoru 57/100, orta puanı gösteriyor. Temel güçlü yan: Focus on the growing cannabis beverage market.. İzlenmesi gereken birincil risk: Potential: Stringent regulations and licensing requirements could limit market access.. Bu bir finansal tavsiye değildir.
KGET MoonshotScore'u nedir?
KGET şu anda MoonshotScore'da 57/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
KGET verileri ne sıklıkla güncellenir?
KGET fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler KGET hakkında ne diyor?
KGET için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
KGET'a yatırım yapmanın riskleri nelerdir?
KGET için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Stringent regulations and licensing requirements could limit market access.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
KGET'ın P/E oranı nedir?
KGET için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için KGET'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
KGET aşırı değerli mi, yoksa düşük değerli mi?
CaliPharms, Inc. (KGET)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
KGET'ın temettü verimi nedir?
CaliPharms, Inc. (KGET) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available for this company. OTC stocks are inherently riskier.